• Home Dutch
  •  EN 
  • Employee login

Quality assessment of pharmacotherapy in patients with chronic kidney disease

Title: Quality assessment of pharmacotherapy in patients with chronic kidney disease
Investigator(s):  Kirsten Smits
Supervisor:  Grigory Sidorenkov
Promotores:  Petra Denig, Gerjan Navis, Henk Bilo
Summary:  Chronic kidney disease (CKD) carries a high burden for poor quality of life and high healthcare costs. Medication to reduce this burden is available but adequate monitoring of optimal use of such treatment is lacking. Quality indicators to evaluate medication treatment for CKD are needed. The aim of this project is to develop, validate and implement a comprehensive set of medication quality indicators for CKD patients. These indicators need to (1) assess medication treatment focusing on efficacy and safety aspects; (2) take into account differentiation for patient characteristics, such as age and disease severity; (3) be reliably measured using data collected from routine practice.
The study consists of four phases recommended for the development and implementation of valid quality indicators. In phase 1, the indicators are developed and judged on reflecting evidence and guideline recommendations by an expert panel, including patient representatives. In phase 2, a cohort study is conducted to test the operational and construct validity using previously collected data from three large medical centers. In a subset of patients, the data from repeated visits will be used to assess continuity of medication treatment. In phase 3, a pilot study will be conducted to implement the indicators in 8 academic and 1 non-academic center. This will provide baseline data, which are used to identify priority areas for improvement. Also, a pilot is conducted to apply the indicators in a primary care cohort. In phase 4, effects of the implementation in the pilot centers are evaluated and a plan for widescale implementation and evaluation is made in cooperation with national organization responsible for measuring and improving quality of care.
Financing:  ZonMw
Start:  1-2-2014
End: 1-2-2017


The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects